Sci Rep:NASH炎症机制得到进一步阐明

2017-10-13 佚名 MedSci原创

非酒精性脂肪性肝炎(NASH)是与酒精无关的常见肝脏疾病,特征是脂肪在肝脏中积聚,并发生炎症和纤维化。全球NASH病例数持续上升,在中国,一些地区的NASH流行率可高达27%。在美国,NASH患者人数也高达1600万。NASH在没有得到有效治疗的情况下可能会诱发严重的肝脏问题,甚至肝癌。但该疾病的炎症方面的机制仍然未知。近日,欧洲多家研究机构的科学家合作在《Scientific Reports》上

非酒精性脂肪性肝炎(NASH)是与酒精无关的常见肝脏疾病,特征是脂肪在肝脏中积聚,并发生炎症和纤维化。全球NASH病例数持续上升,在中国,一些地区的NASH流行率可高达27%。在美国,NASH患者人数也高达1600万。NASH在没有得到有效治疗的情况下可能会诱发严重的肝脏问题,甚至肝癌。但该疾病的炎症方面的机制仍然未知。近日,欧洲多家研究机构的科学家合作在《Scientific Reports》上发文,对其进行了阐述。

以前的研究显示,肝脏炎症与血液源性肝巨噬细胞溶酶体脂质的积累之间有关联,有可能参与NASH的潜在机制。另外,体外研究也表明,特异衍生自氧化型低密度脂蛋白(oxLDL)颗粒的脂质,对从溶酶体去除具有抗性。oxLDL与免疫球蛋白IgM抗体的主要靶标磷酸胆碱(PC)呈分子模拟,通常认为oxLDL和相关脂质在巨噬细胞溶酶体中的积累与炎症增加有关。

在此基础上,研究者调查了血液源性肝巨噬细胞中溶酶体脂质的积累与肝脏炎症是否有因果关系,并评估了增加抗oxLDL IgM自身抗体能影响这种机制到何种程度。研究者创建的小鼠模型证明了溶血素脂质在血液源性肝巨噬细胞介导肝脏炎症和引发纤维化中的作用。此外,研究结果还表明,增加抗oxLDL IgM自身抗体水平能降低炎症。因此,旨在改善脂质诱导的溶酶体功能障碍和阻断oxLDL形成的疗法值得在NASH的背景下做进一步研究。

原始出处:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1301186, encodeId=ccb513011867d, content=<a href='/topic/show?id=38e32852fe' target=_blank style='color:#2F92EE;'>#ASH#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2852, encryptionId=38e32852fe, topicName=ASH)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Sun Oct 15 02:12:00 CST 2017, time=2017-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=252600, encodeId=2ca02526007f, content=henhao, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NcXNhUvfhzd2VdicMnaLeK2Im5gKx4Ucxd8Bwu6S7RG0uILBFQx5HTW2bU4VricDYlQqN20ibASSMYAeGrZrrTpy2Q/0, createdBy=80d11516357, createdName=139****0239, createdTime=Fri Oct 13 15:59:01 CST 2017, time=2017-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=252574, encodeId=a2992525e4a4, content=非常好的文章.学习了.很受益, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7LIiaRZTzJ3SEfiauCzTMPW7YvPPYLNJBXG9oh6Al1icq2VQQkIHWxqXehcicTS62YKJVBhxeth3wggw/0, createdBy=7ce01621306, createdName=天涯183, createdTime=Fri Oct 13 15:10:48 CST 2017, time=2017-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=252542, encodeId=227f2525425e, content=好好学习天天学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Fri Oct 13 12:44:57 CST 2017, time=2017-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=252536, encodeId=6bec2525369e, content=不错的.学习了.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NdqKgfW3nMpOkC3jXxiaW2po0PtglY5ZuVjERqKADW4HyMI8bcZXWlKgH7tEP9ULBoBzuQMibia4pr1s9rQPqLvqQJ/0, createdBy=e8c02060444, createdName=中医痴, createdTime=Fri Oct 13 12:21:42 CST 2017, time=2017-10-13, status=1, ipAttribution=)]
    2017-10-15 kksonne
  2. [GetPortalCommentsPageByObjectIdResponse(id=1301186, encodeId=ccb513011867d, content=<a href='/topic/show?id=38e32852fe' target=_blank style='color:#2F92EE;'>#ASH#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2852, encryptionId=38e32852fe, topicName=ASH)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Sun Oct 15 02:12:00 CST 2017, time=2017-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=252600, encodeId=2ca02526007f, content=henhao, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NcXNhUvfhzd2VdicMnaLeK2Im5gKx4Ucxd8Bwu6S7RG0uILBFQx5HTW2bU4VricDYlQqN20ibASSMYAeGrZrrTpy2Q/0, createdBy=80d11516357, createdName=139****0239, createdTime=Fri Oct 13 15:59:01 CST 2017, time=2017-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=252574, encodeId=a2992525e4a4, content=非常好的文章.学习了.很受益, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7LIiaRZTzJ3SEfiauCzTMPW7YvPPYLNJBXG9oh6Al1icq2VQQkIHWxqXehcicTS62YKJVBhxeth3wggw/0, createdBy=7ce01621306, createdName=天涯183, createdTime=Fri Oct 13 15:10:48 CST 2017, time=2017-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=252542, encodeId=227f2525425e, content=好好学习天天学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Fri Oct 13 12:44:57 CST 2017, time=2017-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=252536, encodeId=6bec2525369e, content=不错的.学习了.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NdqKgfW3nMpOkC3jXxiaW2po0PtglY5ZuVjERqKADW4HyMI8bcZXWlKgH7tEP9ULBoBzuQMibia4pr1s9rQPqLvqQJ/0, createdBy=e8c02060444, createdName=中医痴, createdTime=Fri Oct 13 12:21:42 CST 2017, time=2017-10-13, status=1, ipAttribution=)]
    2017-10-13 139****0239

    henhao

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1301186, encodeId=ccb513011867d, content=<a href='/topic/show?id=38e32852fe' target=_blank style='color:#2F92EE;'>#ASH#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2852, encryptionId=38e32852fe, topicName=ASH)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Sun Oct 15 02:12:00 CST 2017, time=2017-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=252600, encodeId=2ca02526007f, content=henhao, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NcXNhUvfhzd2VdicMnaLeK2Im5gKx4Ucxd8Bwu6S7RG0uILBFQx5HTW2bU4VricDYlQqN20ibASSMYAeGrZrrTpy2Q/0, createdBy=80d11516357, createdName=139****0239, createdTime=Fri Oct 13 15:59:01 CST 2017, time=2017-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=252574, encodeId=a2992525e4a4, content=非常好的文章.学习了.很受益, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7LIiaRZTzJ3SEfiauCzTMPW7YvPPYLNJBXG9oh6Al1icq2VQQkIHWxqXehcicTS62YKJVBhxeth3wggw/0, createdBy=7ce01621306, createdName=天涯183, createdTime=Fri Oct 13 15:10:48 CST 2017, time=2017-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=252542, encodeId=227f2525425e, content=好好学习天天学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Fri Oct 13 12:44:57 CST 2017, time=2017-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=252536, encodeId=6bec2525369e, content=不错的.学习了.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NdqKgfW3nMpOkC3jXxiaW2po0PtglY5ZuVjERqKADW4HyMI8bcZXWlKgH7tEP9ULBoBzuQMibia4pr1s9rQPqLvqQJ/0, createdBy=e8c02060444, createdName=中医痴, createdTime=Fri Oct 13 12:21:42 CST 2017, time=2017-10-13, status=1, ipAttribution=)]
    2017-10-13 天涯183

    非常好的文章.学习了.很受益

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1301186, encodeId=ccb513011867d, content=<a href='/topic/show?id=38e32852fe' target=_blank style='color:#2F92EE;'>#ASH#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2852, encryptionId=38e32852fe, topicName=ASH)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Sun Oct 15 02:12:00 CST 2017, time=2017-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=252600, encodeId=2ca02526007f, content=henhao, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NcXNhUvfhzd2VdicMnaLeK2Im5gKx4Ucxd8Bwu6S7RG0uILBFQx5HTW2bU4VricDYlQqN20ibASSMYAeGrZrrTpy2Q/0, createdBy=80d11516357, createdName=139****0239, createdTime=Fri Oct 13 15:59:01 CST 2017, time=2017-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=252574, encodeId=a2992525e4a4, content=非常好的文章.学习了.很受益, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7LIiaRZTzJ3SEfiauCzTMPW7YvPPYLNJBXG9oh6Al1icq2VQQkIHWxqXehcicTS62YKJVBhxeth3wggw/0, createdBy=7ce01621306, createdName=天涯183, createdTime=Fri Oct 13 15:10:48 CST 2017, time=2017-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=252542, encodeId=227f2525425e, content=好好学习天天学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Fri Oct 13 12:44:57 CST 2017, time=2017-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=252536, encodeId=6bec2525369e, content=不错的.学习了.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NdqKgfW3nMpOkC3jXxiaW2po0PtglY5ZuVjERqKADW4HyMI8bcZXWlKgH7tEP9ULBoBzuQMibia4pr1s9rQPqLvqQJ/0, createdBy=e8c02060444, createdName=中医痴, createdTime=Fri Oct 13 12:21:42 CST 2017, time=2017-10-13, status=1, ipAttribution=)]
    2017-10-13 忠诚向上

    好好学习天天学习

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1301186, encodeId=ccb513011867d, content=<a href='/topic/show?id=38e32852fe' target=_blank style='color:#2F92EE;'>#ASH#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2852, encryptionId=38e32852fe, topicName=ASH)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Sun Oct 15 02:12:00 CST 2017, time=2017-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=252600, encodeId=2ca02526007f, content=henhao, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NcXNhUvfhzd2VdicMnaLeK2Im5gKx4Ucxd8Bwu6S7RG0uILBFQx5HTW2bU4VricDYlQqN20ibASSMYAeGrZrrTpy2Q/0, createdBy=80d11516357, createdName=139****0239, createdTime=Fri Oct 13 15:59:01 CST 2017, time=2017-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=252574, encodeId=a2992525e4a4, content=非常好的文章.学习了.很受益, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7LIiaRZTzJ3SEfiauCzTMPW7YvPPYLNJBXG9oh6Al1icq2VQQkIHWxqXehcicTS62YKJVBhxeth3wggw/0, createdBy=7ce01621306, createdName=天涯183, createdTime=Fri Oct 13 15:10:48 CST 2017, time=2017-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=252542, encodeId=227f2525425e, content=好好学习天天学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Fri Oct 13 12:44:57 CST 2017, time=2017-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=252536, encodeId=6bec2525369e, content=不错的.学习了.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NdqKgfW3nMpOkC3jXxiaW2po0PtglY5ZuVjERqKADW4HyMI8bcZXWlKgH7tEP9ULBoBzuQMibia4pr1s9rQPqLvqQJ/0, createdBy=e8c02060444, createdName=中医痴, createdTime=Fri Oct 13 12:21:42 CST 2017, time=2017-10-13, status=1, ipAttribution=)]
    2017-10-13 中医痴

    不错的.学习了.谢谢分享!

    0

相关资讯

Hepatology:抑制单核细胞再浸润,改善脂肪性肝炎和肝纤维化

药物抑制CCR2阳性的单核细胞再浸润,显著地改善了胰岛素抵抗、肝脏炎症和肝纤维化,证实了CVC对NASH患者的治疗潜力。

Hepatology:Cenicriviroc治疗非酒精性脂肪性肝炎相关肝纤维化的随机、安慰剂对照试验

CVC治疗1年后,相比安慰剂对照组,两倍的患者肝纤维化得到改善,并且非酒精性脂肪性肝炎没有恶化。Cenicriviroc所展现出的抗纤维化作用值得进一步关注。

Hepatology:非酒精性脂肪性肝病流行率模型预测疾病负担呈指数形式递增

非酒精性脂肪性肝病(NAFLD)和由NAFLD导致的非酒精性脂肪性肝炎(NASH)在美国高度流行,导致肝硬化和肝细胞癌发病不断增加,逐渐成为肝移植手术指征。本研究采用马尔科夫模型预测NAFLD疾病进展。

Hepatolog:肥胖和非酒精性脂肪性肝炎相关肝移植患者数量将增加

鉴于人群中肥胖流行趋势,预计因NASH相关肝硬化导致的肝移植将显著增加。需要持续的努力以遏制肥胖的流行,以减少未来NASH相关负担。

Hepatology:肝纤维化分期而非非酒精性脂肪性肝炎可预测患者死亡率和发展为严重肝病的时间

在平均20年的随访中(范围:0-40),相当于13163人年,12%的NAFLD患者和2.2%的正常对照发展为严重肝病(p<0.001)。相比正常对照,严重肝病的风险随着肝纤维化分期的增加而增高。

JAMA DERMAT:NASH FbiroSure可以用于监测长期接受甲氨蝶呤治疗的银屑病患者肝硬化恶化的风险

肝毒性作用对银屑病患者的长期影响是不典型的。近日,在医学权威杂志JAMA上面发表了一篇研究文章,该文章旨在研究一种无创监测方法来检测长期接受甲氨蝶呤治疗的银屑病患者中肝硬化的发生发展。非酒精性脂肪肝(NASH)和肝硬化的一种无创性检查方法——FibroSure,是否可以用来帮助确定银屑病患者甲氨蝶呤(MTX)钠药物治疗的资格,监测MTX诱发的肝毒性作用,以及监测MTX治疗期间肝硬化的恶化程度?